据J&J和Protagonist报道,ICOTYDE的一年数据显示皮肤清除率高且对口腔牛皮的安全性很强. J&J and Protagonist report one-year ICOTYDE data shows high skin clearance and safety for oral psoriasis.

约翰逊和强生以及Protagonist Therapeutics公司公布了ICOTYDE的一年数据,该药物是口服牛皮治疗的药物,显示其完全清除皮肤率高,并且在成人和青少年中具有良好的安全性. Johnson & Johnson and Protagonist Therapeutics released one-year data for ICOTYDE, an oral psoriasis treatment, showing high rates of complete skin clearance and a favorable safety profile in adults and adolescents. 这种针对IL-23受体的药物在52周内表现出持续有效性,没有新的安全问题. The drug, which targets the IL-23 receptor, demonstrated sustained effectiveness over 52 weeks with no new safety concerns.